India Pharma Outlook Team | Tuesday, 09 June 2026
India’s anti-obesity drug market is slowing after a semaglutide-led boom, as generic sales growth moderated following the initial surge triggered by lower-cost alternatives in March.
According to data from PharmaTrac, sales of non-proprietary semaglutide equivalents have begun to plateau after the initial affordability-driven rush, with month-on-month unit growth slowing to 12% in May from 88% in April.
The slowdown suggests that the first wave of eligible patients has already entered treatment following the introduction of lower-cost alternatives. While demand remains strong, market growth is now transitioning into a more gradual phase driven by physician adoption, patient education, and healthcare infrastructure.
According to PharmaTrac, the strong momentum seen in April eased in May as the market absorbed its initial surge of patients. The flattening has occurred earlier than is typically observed with generic drug launches, where sales usually take three to four months to stabilize.
One major factor has been the response of Novo Nordisk, which reduced prices of its semaglutide products Ozempic and Wegovy as generic manufacturers entered the market. The narrowing price gap between generic versions and the innovator products has influenced prescribing and purchasing decisions.
“The initial euphoria is coming down,” said Neeraj Tulara, a Mumbai-based diabetologist and general medicine expert. “The pricing difference between generic semaglutide and the innovator molecule from Novo Nordisk is not very significant. Hence, many are preferring to opt for the original molecule.”
India’s anti-obesity market, now valued at over Rs 1,900 crore, has emerged as one of the country’s fastest-growing therapy segments. Semaglutide and tirzepatide together account for more than 90% of the market, attracting significant competition since semaglutide lost patent protection at the end of March.
Doctors and industry experts believe that future growth in the generic semaglutide segment will depend less on pricing and more on ecosystem development. Early adopters have largely consisted of obesity specialists, diabetologists, and affluent patients familiar with innovator therapies.
According to leading diabetologist Rajiv Kovil, the next wave of adoption is expected to come from physicians, gastroenterologists, pulmonologists, and cardiologists. However, broader uptake will require training of support staff and better clinic infrastructure to administer injectable therapies effectively.
Medical experts have also pointed to patient discontinuation as a factor contributing to slower sales growth. Poor counseling and affordability concerns continue to impact long-term adherence.
“The majority of the time, discontinuation is related to poor counseling,” said Kovil. “Also, on the affordability front, even a cost price of Rs 2,000 per month is expensive by Indian standards.”
Although generic semaglutide products are cheaper than branded alternatives, monthly treatment costs of Rs 2,000-4,000 remain high for many patients, particularly in tier-II and tier-III cities. Experts also cite a limited pool of eligible patients and government advisories as factors constraining rapid expansion.
Also Read: Are Next-Gen Obesity Drugs Evolving into Multi-Disease Therapies?
Industry observers expect growth in the generic semaglutide market to continue, albeit at a measured pace. Future expansion is likely to depend on physician experience, patient awareness, and the gradual development of a supportive treatment ecosystem.
“Slowly, the incremental value of prescribers will go up,” said Kovil. “That will come with their own experience, training of staff, and ecosystem development, which may take up to a year or two.”
At the same time, tirzepatide has demonstrated resilience despite concerns that lower-cost semaglutide alternatives would erode demand. Monthly sales of tirzepatide products recovered from Rs 114 crore in March to Rs 136 crore in May, returning to levels seen before generic competition intensified.
The slowdown in semaglutide growth suggests that India’s anti-obesity drug market is moving from an initial launch-driven phase into a more sustainable adoption cycle. While affordability remains a key advantage for generics, physician confidence, patient adherence, and treatment infrastructure will increasingly determine market growth.
Tirzepatide’s recovery also highlights the continued demand for differentiated therapies. Market participants are closely watching prescribing trends as physicians evaluate efficacy, pricing, and patient outcomes across competing treatments.
With around 35 semaglutide brands from 17 companies currently competing for market share, experts caution that aggressive primary stocking could lead to inventory build-up if consumer demand does not keep pace.
India’s anti-obesity drug market remains one of the fastest-growing segments in the pharmaceutical industry, but the initial surge following generic semaglutide launches is beginning to moderate.
As the market matures, growth is expected to be driven less by pricing advantages and more by physician adoption, patient education, and healthcare ecosystem development, while competition between semaglutide and tirzepatide continues to shape the sector’s evolution.
.jpg)
